Build a vaccine architecture – editorials

Rarely have the worlds of science, public health, economy and global balance of power intersected as they have in times of Covid-19. And rarely has so much hinged on a single variable — the development of a vaccine, or a set of vaccines, to provide immunity to every individual across the world from Sars-CoV-2. The good news is that the worst may be behind us: The world is close to a vaccine breakthrough. Pfizer and Moderna have achieved a high degree of efficacy — at over 90%, it is much safer than initially assumed — using radical technologies which have the potential to tackle other critical diseases. There are other vaccines too, many at the third stage of trial, with a high possibility of success. All of this means that by early next year, the world will have a basket of vaccine options on the menu to choose from. Health

Read More

Oxford vaccine shows promise; Europe sees decline in new cases; pork plant managers bet on number of infections

The U.S. death toll from coronavirus has surpassed 250,000, including 1,700 reported Wednesday alone. Hospitalizations across the nation have exploded, with almost 80,000 Americans now receiving inpatient treatment.

COVID-19 has now killed a quarter of a million Americans



Still, some governors remain unconvinced that mandatory facial coverings are a necessary tool in curbing the pandemic. 

Thirty-six states have some type of statewide mask requirement. The District of Columbia and Puerto Rico require them, too. Arizona Gov. Doug Ducey and South Dakota Gov. Kristi Noem, a fast-rising GOP star, are among the headliner holdouts. Both spoke to the media this week. Neither budged from their position.

Start the day smarter. Get all the news you need in your inbox each morning.

Ducey, in his first news pandemic briefing since Oct. 29, held a moment of silence and prayed for victims. But he suggested that a statewide

Read More

Pfizer seeks vaccine approval within days; Home test ok’d


It’s nearly impossible to fathom the number of cases and deaths from the COVID-19 virus, so we added some geographical perspective.


Pfizer and BioNTech plan to submit a request “within days” to the Food and Drug Administration for emergency-use approval of a vaccine they say has shown to be 95% effective in mass testing.

“Our objective from the very beginning was to design and develop a vaccine that would generate rapid and potent protection against COVID-19 with a benign tolerability profile across all ages,” said Ugur Sahin, M.D., CEO of BioNTech. “We believe we have achieved this.”

The companies said they expect to produce up to 50 million vaccine doses globally by year’s end and up to 1.3 billion doses by the end of 2021. Experts say frontline healthcare workers are expected to be first in line for inoculation.

The Phase 3 clinical trial began on July

Read More

Zoom, Peloton, and other ‘stay-at-home’ stocks tumble after Moderna’s COVID-19 vaccine proves extremely effective

  • “Stay-at-home” stocks including Zoom, Etsy, and Peloton tumbled in pre-market trading on Monday after Moderna revealed its COVID-19 vaccine was almost 95% effective in a late-stage trial.
  • Docusign, Wayfair, Fastly, and other stocks that have at least partly benefited from the pandemic also retreated.
  • In contrast, airlines, cruise lines, manufacturers, and other “real economy” stocks jumped as investors wagered the vaccine would allow economies to reopen in a matter of months.
  • Visit Business Insider’s homepage for more stories.

Zoom, Etsy, Peloton, and other “stay-at-home” stocks slumped in pre-market trading on Monday, as positive vaccine news dampened their growth prospects.

Moderna’s announcement that its COVID-19 vaccine proved 94.5% effective in a late-stage trial helped to drive Zoom shares down as much as 7%, Etsy down 6%, and Peloton down 5%.

Netflix, Pinterest, Docusign, Wayfair, Fastly, Chegg, and other companies that have benefited from people spending more time at home

Read More

North Dakota mask mandate; Steve Sisolak; Trump vaccine


Public health experts say this year everyone should get a flu shot, if possible.


Many Americans are bracing for increased virus restrictions and the possibility of fall and winter lockdowns, even as leaders in some areas are doubling-down on their hands-off approach.

The nation’s surge in cases continues: On Friday, the U.S. recorded 184,514 new daily infections, breaking yet another record, according to Johns Hopkins University data. The U.S. first surpassed 100,000 new daily cases on Nov. 5 and has continued to break the daily record since then.

Meanwhile, Nevada Democratic Gov. Steve Sisolak, who tested positive for the virus on Friday, has repeatedly argued that containing the virus is largely up to individuals. Texas Gov. Greg Abbott has emphasized new treatments and vaccines that are expected to become available soon.

South Dakota Gov. Kristi Noem’s office said she has no intention of using state resources to

Read More

What The Vaccine Really Means For Work From Home Stocks

Work and learn from home stocks have had a solid run this year, as Covid-19 drives demand for connectivity, collaboration, and cybersecurity-related software. For perspective, our indicative theme of Work And Learn From Home Stocks is up by over 190% year-to-date on an equally weighted basis. However, a Coronavirus vaccine is looking like a real possibility in the coming quarters, following the surprisingly strong efficacy data for Pfizer’s
vaccine candidate which was released earlier this week. So what does this mean for work from home stocks? While

Read More

Canada bets on imports as home-grown COVID-19 vaccine heads to large-scale trials

TORONTO (Reuters) – Canada’s reliance on supply contracts to secure COVID-19 vaccines from drugmakers like Pfizer Inc has put daily life for Canadians, and prospects for the economy over the next year, in the hands of a few foreign companies facing overwhelming global demand.

Medicago employees harvest Nicotiana benthamiana plants to extract virus-like particles (VLP) in Medicago’s Durham Facility in Durham, North Carolina, U.S. in an undated photograph. Medicago/Handout via REUTERS.

As other governments pour hundreds of millions or billions into vaccine development, Canada has earmarked C$1 billion ($761 million) to buy doses abroad. Meanwhile, Quebec-based Medicago has worked with a shoestring budget on its home-grown, plant-based vaccine.

Medicago, owned by Japan’s Mitsubishi Tanabe Pharma and tobacco company Philip Morris, reported promising early trial data this week and said on Thursday it plans to begin large-scale studies. The vaccine uses an efficacy booster from GlaxoSmithKline called an adjuvant.

If pivotal

Read More

Wall Street Favoring Stay-At-Home Trade As Virus Cases Mount And Vaccine Still A Ways Away

Key Takeaways:

  • Initial jobless claims number came in at a less-than-expected 709,000
  • Headline, core CPI data show no monthly change in inflation
  • VIX, gold move higher; 10-year Treasury yield dips

This week, the stock market has seen a tug of war between growth stocks and value names as investors have been rethinking the balance between companies that would benefit from an economic reopening and those that would be helped if people stay at home longer.

This morning it seems that investors are leaning slightly toward the stay-at-home end of the pendulum swing, perhaps as a result of coronavirus cases that continue to mount ahead of the coldest months of the year and the realization that a vaccine likely will still take some time for approval and wide distribution. That likely means more economic pain for longer, especially for small businesses.

While the stock market this morning

Read More

Zoom And Other Stay-At-Home Stocks Pull Back After Positive Vaccine News. How Attractive Are They Now?

Certain companies have been clear beneficiaries of the coronavirus pandemic, as consumers’ behaviors changed and people stayed close to home. We don’t know when the market’s preferences will change or if they are temporary, but shares of stay-at-home stocks fell sharply on Monday following the release of encouraging coronavirus vaccine news.

The coronavirus pandemic, while better understood than it was at the beginning of the year, still presents significant uncertainty in terms of how it will impact society and the economy. Despite the long-term uncertainty, positive preliminary vaccine and antibody treatment news this week from major pharmaceutical companies led investors to abandon (at least temporarily) popular stay-at-home stocks Teladoc Health, UPS and Zoom Video.

Shares of Teladoc Health
traded nearly 14% lower on Monday, while Zoom Video Communications (ZM) declined more than 17%. The pullbacks came after Pfizer
and BioNTech SE (BNTX) reported that their coronavirus vaccine candidate

Read More